Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Crivit
Crivit Apr. 2 at 8:00 PM
$MREO https://investorshub.advfn.com/p.php?pid=staticchart&s=mreo&p=0&t=17&showctype=1&width=800&vol=1&height=400&Vol=1
0 · Reply
ParallelPort
ParallelPort Apr. 2 at 2:47 PM
$MREO $BMEA $EVMN This will only be one of a couple multi tags before just singular. Starting this weekend i will be diving into BMEA and EVMN to go alongside MREO. What i post is neither bear nor bull, i try to keep it factual with just a few opinions. I know there are others on these boards who understand these companies trials and drugs better than i so i will leave that with them and hopefully elighten you all on other aspects. All three of these tickers i believe (my opinion) will at least +50% over the next 3 to 4 months, with shorter time frames for some, and higher percentages for others. I appreciate you all.
0 · Reply
ParallelPort
ParallelPort Mar. 30 at 5:28 PM
$MREO So i wanted to give a little update what is currently happening. There was a PRE 14A (Preliminary Proxy) filed on March 27 indicating the company is seeking shareholder authority at the May AGM to allot shares, providing them the legal mechanism to raise capital if a favorable window opens. Also the departure of Dr. Jenkins ties in. Dr. Jenkins has a reputation in the biotech world (as a former CEO and FDA Science Board member) for being highly focused on regulatory accountability. She wasn't a "legacy" director; she was a watchdog. Her departure suggests one less voice in the room that is strictly beholden to Rubric’s initial mandate for radical change. Proposal 10 (authority to allot shares) is the big one. This is the company asking for the power to issue more stock (dilute). Losing a director who was a staunch advocate for "shareholder value over dilution" right before this vote is a notable coincidence.
1 · Reply
ParallelPort
ParallelPort Mar. 30 at 5:28 PM
$MREO I wanted to give a little info on any possible R/S. Being an ADS effectivly can split the stock without a R/S, or a shareholder vote, which is why a R/S vote is not on the May docket. It is possible the offering authorization could tie into the ADS Ratio Change by middle to end of summer. Full Reverse Split (UK Level): Consolidates the underlying ordinary shares. This requires a shareholder vote and is a complex legal process in the U.K. ADS Ratio Change (Depositary Level): The Board can simply instruct its depositary bank (Citibank) to change the ratio of ordinary shares per ADS (e.g., from 1:5 to 1:50). The "Secret": This does NOT require a shareholder vote. It is an administrative change to the Deposit Agreement. Effect: The price on your screen multiplies (e.g., $0.35 becomes $3.50
0 · Reply
Crivit
Crivit Mar. 26 at 7:56 PM
0 · Reply
Newcar
Newcar Mar. 26 at 5:07 PM
$MREO when Reverse Split? Scam company
0 · Reply
SebNo1234
SebNo1234 Mar. 24 at 6:17 PM
$MREO https://de.investing.com/news/analyst-ratings/baird-bestatigt-rating-fur-mereo-biopharma-nach-zahlenvorlage-93CH-3400990
0 · Reply
YakingBio
YakingBio Mar. 24 at 4:36 PM
$MREO big dump. Its over u fuckas
0 · Reply
Crivit
Crivit Mar. 23 at 2:49 PM
$MREO you
0 · Reply
YakingBio
YakingBio Mar. 23 at 2:22 PM
$MREO Fuck
0 · Reply
Latest News on MREO
Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs


Crivit
Crivit Apr. 2 at 8:00 PM
$MREO https://investorshub.advfn.com/p.php?pid=staticchart&s=mreo&p=0&t=17&showctype=1&width=800&vol=1&height=400&Vol=1
0 · Reply
ParallelPort
ParallelPort Apr. 2 at 2:47 PM
$MREO $BMEA $EVMN This will only be one of a couple multi tags before just singular. Starting this weekend i will be diving into BMEA and EVMN to go alongside MREO. What i post is neither bear nor bull, i try to keep it factual with just a few opinions. I know there are others on these boards who understand these companies trials and drugs better than i so i will leave that with them and hopefully elighten you all on other aspects. All three of these tickers i believe (my opinion) will at least +50% over the next 3 to 4 months, with shorter time frames for some, and higher percentages for others. I appreciate you all.
0 · Reply
ParallelPort
ParallelPort Mar. 30 at 5:28 PM
$MREO So i wanted to give a little update what is currently happening. There was a PRE 14A (Preliminary Proxy) filed on March 27 indicating the company is seeking shareholder authority at the May AGM to allot shares, providing them the legal mechanism to raise capital if a favorable window opens. Also the departure of Dr. Jenkins ties in. Dr. Jenkins has a reputation in the biotech world (as a former CEO and FDA Science Board member) for being highly focused on regulatory accountability. She wasn't a "legacy" director; she was a watchdog. Her departure suggests one less voice in the room that is strictly beholden to Rubric’s initial mandate for radical change. Proposal 10 (authority to allot shares) is the big one. This is the company asking for the power to issue more stock (dilute). Losing a director who was a staunch advocate for "shareholder value over dilution" right before this vote is a notable coincidence.
1 · Reply
ParallelPort
ParallelPort Mar. 30 at 5:28 PM
$MREO I wanted to give a little info on any possible R/S. Being an ADS effectivly can split the stock without a R/S, or a shareholder vote, which is why a R/S vote is not on the May docket. It is possible the offering authorization could tie into the ADS Ratio Change by middle to end of summer. Full Reverse Split (UK Level): Consolidates the underlying ordinary shares. This requires a shareholder vote and is a complex legal process in the U.K. ADS Ratio Change (Depositary Level): The Board can simply instruct its depositary bank (Citibank) to change the ratio of ordinary shares per ADS (e.g., from 1:5 to 1:50). The "Secret": This does NOT require a shareholder vote. It is an administrative change to the Deposit Agreement. Effect: The price on your screen multiplies (e.g., $0.35 becomes $3.50
0 · Reply
Crivit
Crivit Mar. 26 at 7:56 PM
0 · Reply
Newcar
Newcar Mar. 26 at 5:07 PM
$MREO when Reverse Split? Scam company
0 · Reply
SebNo1234
SebNo1234 Mar. 24 at 6:17 PM
$MREO https://de.investing.com/news/analyst-ratings/baird-bestatigt-rating-fur-mereo-biopharma-nach-zahlenvorlage-93CH-3400990
0 · Reply
YakingBio
YakingBio Mar. 24 at 4:36 PM
$MREO big dump. Its over u fuckas
0 · Reply
Crivit
Crivit Mar. 23 at 2:49 PM
$MREO you
0 · Reply
YakingBio
YakingBio Mar. 23 at 2:22 PM
$MREO Fuck
0 · Reply
ParallelPort
ParallelPort Mar. 23 at 12:29 AM
$MREO There was a count of 14 large sell blocks hitting the tape in the afternoon vs. only 2 in the morning suggests that the selling was not "random" retail panic, but rather a deliberate institutional wind-down. Here is the breakdown of what was likely at play. That "two-speed" trading day on Friday—where the tape was quiet in the morning but turned heavy with block sales after 12:00 PM—is a classic signature of the intersection between fundamental exits and mechanical rebalancing. While the "Witching Hour" technically refers to the final 60 minutes of trading (3:00–4:00 PM), large institutional desks and ETFs typically start their "mandatory" rebalancing and position-rolling around noon to find liquidity without causing a total price collapse.
0 · Reply
ParallelPort
ParallelPort Mar. 23 at 12:29 AM
$MREO There is also the possibility of Short Repositioning. On a Witching Friday, shorts often use these large "sell-side" blocks to keep the price pinned below a certain level (in this case, $0.35) to prevent their own positions from being squeezed. The fact that the stock "absorbed" 14 large blocks and still held near the $0.34–$0.35 range is actually a sign of some underlying resilience. On a normal day, that many "sell" blocks would likely have triggered a far more violent breakdown.
0 · Reply
Svetli_stock
Svetli_stock Mar. 20 at 8:49 PM
0 · Reply
LDT79
LDT79 Mar. 20 at 8:11 PM
$MREO go to hell - never ever trust a DEI CEO
0 · Reply
Crivit
Crivit Mar. 20 at 8:56 AM
$MREO https://x.com/ej23ny/status/2034688359704981570?s=46&t=bEBIliluVsTI7poV3L9h2Q
1 · Reply
SebNo1234
SebNo1234 Mar. 20 at 7:47 AM
$MREO https://www.investing.com/news/analyst-ratings/mereo-biopharma-stock-maintained-at-buy-by-btig-on-regulatory-pathway-93CH-4571789
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 4:32 PM
$MREO So good news first, it broke the .35 resistance but bounced right back and held. Institutions are cash dry to by so they can only hold it up on low volume days. Got earnings a week early, here is something that caught my eye in the report. Management has re-emphasized the "totality of the data," highlighting significant gains in Bone Mineral Density (BMD) and a reduction in vertebral fractures, stating these results "may provide the basis for engagement with the regulatory agencies." With words like "may provide" that doesn't sound very positive. And yesterday actual material news from one of the lawsuits.The lawsuit specifically targets the "BMD-to-Fracture" correlation. It claims management touted a 67% reduction in Phase 2 data while allegedly knowing the data lacked the control groups necessary to establish causation. This is the first specific accusation named in any suit which spooked investors and helped drop the price yesterday. Maybe "may provide" is because of lawsuits.
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 2:23 PM
$MREO Will post around lunch the reasons for the drop. Couple of interesting tidbits from the last two days to catch you up on.
0 · Reply
Teamtalk2014
Teamtalk2014 Mar. 19 at 1:44 PM
$MREO Earliest yearly results. Missed Leerink recently while Ultragenx presented, website appears relatively static with partial metadata visible.
0 · Reply
davedtire
davedtire Mar. 19 at 12:59 PM
$MREO https://elite.finviz.com/news/338678/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate-highlights
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 19 at 12:42 PM
$MREO RSI: 39.81, MACD: -0.0380 Vol: 0.02, MA20: 0.40, MA50: 0.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LDT79
LDT79 Mar. 18 at 3:48 PM
$MREO what a shit show and CEO is still there
0 · Reply